Home » Newsletters » BioWorld Asia

BioWorld Asia

March 10, 1999

View Archived Issues

Amrad Sells Baxter Rights To Heart Protein For $22M

NeuroSearch, P&U Ending Deal On Anxiety Treatment

On-The-Spot Tests Could Let Physicians Identify Genotype, Determine Strongest Treatment

Oxford Ends Year Strong; Deals Fuel Cash Position

Inpharmatica Raises #3M In Second Financing Round

RPR Joins Genetics Institute Roster Of Database Buyers

Axis, Roche Join Forces To Test Animal Vaccines

Chiroscience Regains Rights To Lead Anesthetic Product

Actinova In Three-Way Pact For Streptococcus Vaccine

Oxford BioMedica Raising #3.6M For Cancer Study

SR Pharma, Corixa Enter Second Licensing Deal

Stocks Follow Biota Slide After Flu Drugs Refusal

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...